Rheumatoid arthritis Trials in Elche, Spain
Conditions / Rheumatoid arthritis / Elche, Spain
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
15 total trials for this combination
Showing top 10 of 15 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03915964 | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis | COMPLETED | PHASE4 |
| NCT01894516 | Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2) | COMPLETED | PHASE2 |
| NCT00234884 | Post-marketing Observational Study in Subjects With Rheumatoid Arthritis | COMPLETED | — |
| NCT02049138 | An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis | COMPLETED | PHASE2 |
| NCT02675426 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone | COMPLETED | PHASE3 |
| NCT04413617 | TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE | COMPLETED | PHASE2 |
| NCT00750880 | An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. | COMPLETED | PHASE3 |
| NCT01647451 | A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis | COMPLETED | PHASE2 |
| NCT01888874 | Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1) | COMPLETED | PHASE2 |
| NCT00883753 | An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy | COMPLETED | PHASE3 |